The Competition Commission of India (CCI) has approved the acquisition of Corporate restructuring of GlaxoSmithKline Consumer Healthcare Holdings (No.2) (JVCO) under Section 31(1) of the Competition Act, 2002.

The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger and the share exchange steps involving the shareholders of JVCO. Immediately following completion of the demerger and share exchange steps, the shareholding of Haleon will be held by a combination of GSK, GSK’s affiliates and GSK’s shareholders (together representing 68 per cent of Haleon's voting rights) and (directly/indirectly) Pfizer (representing 32 per cent of Haleon's voting rights). 

GSK, registered in the UK, is a pharmaceuticals company active worldwide in the research, development, manufacturing, and marketing of prescription pharmaceuticals, vaccines and consumer healthcare products. In the consumer healthcare segment, it is active in the research, development, manufacturing, and marketing of products which are typically available without prescription (i.e., OTC), for various indications. 

Pfizer is a research-based biopharmaceutical company and is engaged globally in the research, development, manufacturing, and marketing of innovative medicines.

Haleon is a new incorporated entity that presently does not have any business activities.

JVCO was established in 2019, combining the respective legacy consumer healthcare business worldwide, including India, of GSK and Pfizer. JVCO (through its subsidiaries and affiliates) is engaged in the manufacture and distribution of consumer healthcare products.